The effect of the 21-aminosteroid U74006F on the clinical course of acute experimental allergic encephalomyelitis.
We evaluated the clinical effect of several doses of the 21-aminosteroid U74006F in acute experimental autoimmune encephalomyelitis (EAE) and compared it with the administration of methylprednisolone (MP). There was no significant change in the clinical course of EAE with the dosages we used, whereas the effect of MP was unquestionably beneficial. Based on these results U74006F does not seem to be a promising drug for the treatment of exacerbations of multiple sclerosis.
Uitdehaag
B M
BM
Department of Neurology, Free University Hospital, Amsterdam, Netherlands.
Polman
C H
CH
Sontrop
K
K
Dijkstra
C D
CD
D000208:Acute Disease; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000494:pharmacology; D011281:Pregnatrienes / Q000494:pharmacology*; D051381:Rats; D011917:Rats, Inbred Lew
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D011281:Pregnatrienes; D008775:Methylprednisolone; C053355:tirilazad